- Home
- MREO vs ETON Comparison
MREO vs ETON Comparison
Compare MREO & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- ETON
- Stock Information
- Founded
- MREO 2015
- ETON 2017
- Country
- MREO United Kingdom
- ETON United States
- Employees
- MREO N/A
- ETON N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- MREO Health Care
- ETON Health Care
- Exchange
- MREO Nasdaq
- ETON Nasdaq
- Market Cap
- MREO 424.5M
- ETON 428.5M
- IPO Year
- MREO N/A
- ETON 2018
- Fundamental
- Price
- MREO $2.85
- ETON $13.57
- Analyst Decision
- MREO Strong Buy
- ETON Strong Buy
- Analyst Count
- MREO 7
- ETON 3
- Target Price
- MREO $7.71
- ETON $29.67
- AVG Volume (30 Days)
- MREO 1.2M
- ETON 465.6K
- Earning Date
- MREO 08-12-2025
- ETON 08-07-2025
- Dividend Yield
- MREO N/A
- ETON N/A
- EPS Growth
- MREO N/A
- ETON N/A
- EPS
- MREO N/A
- ETON N/A
- Revenue
- MREO N/A
- ETON $48,327,000.00
- Revenue This Year
- MREO N/A
- ETON $103.21
- Revenue Next Year
- MREO $54.07
- ETON $51.34
- P/E Ratio
- MREO N/A
- ETON N/A
- Revenue Growth
- MREO N/A
- ETON 40.88
- 52 Week Low
- MREO $1.58
- ETON $3.18
- 52 Week High
- MREO $5.02
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- MREO 64.74
- ETON 26.42
- Support Level
- MREO $2.61
- ETON $13.20
- Resistance Level
- MREO $2.85
- ETON $19.35
- Average True Range (ATR)
- MREO 0.17
- ETON 0.93
- MACD
- MREO 0.03
- ETON -0.49
- Stochastic Oscillator
- MREO 88.83
- ETON 6.02
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.